Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 26;14:120. doi: 10.1186/s13000-019-0901-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — The survival analysis of ccRCC patients for the expressions of PRMT1 and ZEB1 in cancer cells, tumor grade and stage (a-d) and qRT-PCR analysis of PRMT1 in ccRCC (E-H). (a-b) Cancer-specific survival rates, revealed by Kaplan-Meier survival analysis, were higher in patients whose cancer cells were positive for both PRMT1 and ZEB1, than those who were negative for both of the markers, (c) Cancer-specific survival rate was lower in patients with high-grade carcinomas, when compared to the patients with low-grade carcinomas, (d) Cancer-specific survival rate was lower in patients with high stage tumors, in comparison to the patients with low stage tumor disease and partial nephrectomy; (e) mRNA PRMT1 expression was decreased in tumor tissue, related to adjacent non-tumor parenchyma, (f) Relative mRNA PRMT1 expression decrease was observed in high-grade tumors, when compared to low grade tumors; (g) Gradual decrease of mRNA PRMT1 was observed by each increase of tumor stage; (h) The graph illustrates the tendency of mRNA PRMT1 expression level decrease by the increase in tumor size; Relative mRNA expression levels are presented with mean values (+/− 1 SD)